CVS Stock Analysis: Buy, Sell, or Hold?

CVS - CVS HEALTH CORPORATION

RETAIL-DRUG STORES AND PROPRIETARY STORES
$104.43
-0.79 (-0.75%) ▼
5d: -3.07%
30d: -0.36%
90d: +25.38%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026 1d
Smart Money Distribution

None View Scanner →

Strength: 6.5/10

Get Alerted When CVS Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
💡 BUY OPPORTUNITY: CVS shows positive signals but monitor for confirmation. Market pricing in 4.9% annual growth which appears achievable. Moderate conviction.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$135.19
Based on 8.5% avg growth
INTRINSIC VALUE TODAY
$83.94
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.7x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: CVS is currently trading at $104.43, which is considered fair relative to its 30-day fair value range of $103.02 to $107.53. From a valuation perspective, the stock is trading at a premium (Forward PE: 12.4) compared to its historical average (10.7). At these levels, the market is pricing in 4.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, CVS is in a strong uptrend. The price is currently testing key support at $103.01. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position FAIR
Historical Trading Range $103.02 - $107.53
Company Quality Score 51/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 66.7%

All Signals

  • NEUTRAL: Price in fair range
  • NEUTRAL: Mixed technical signals (40/100)
  • BULLISH: High volume confirmation
  • NEUTRAL: Near Wall St target ($113.50)
  • NEUTRAL: Trading at premium valuation - market expects 4.9% growth which is achievable

Trading Range Analysis

30-Day Trading Range $103.02 - $107.53
Current vs Trading Range FAIR

Support & Resistance Levels

Support Level $103.01
Resistance Level $110.68
Current Trend Strong Uptrend
Technical data as of Jul 31, 2026

Fundamental Context

Forward P/E (Next Year Est.) 12.40
Wall Street Target $113.50 (+8.7%)
Revenue Growth (YoY) 6.1%
Earnings Growth (YoY) 63.1%
Profit Margin 0.7%
Valuation Premium vs History +4.9% premium
PE vs Historical 12.4 vs 10.7 STRETCHED
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +4.9% (market-implied from PE analysis)
1-Year Target $109.55 (+5%)
2-Year Target $114.91 (+10%)
3-Year Target $120.55 (+15%)
3-Yr Target (if PE normalizes) (PE: 12→11) PE COMPRESSION $104.00 (0%)
Earnings growth offset by PE compression
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 20.7, Growth: 13.0%) $251.75 (+141%)
Base: (SPY PE: 12.4, Growth: 13.0%) $150.61 (+44%)
Bear: (PE: 10.5, Growth: 13.0%) $128.02 (+23%)
📈 Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (47x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 46.56 | Current EPS (TTM): $2.26
Bull Case $231.48 (+122%)
Analyst growth 100.0%, PE expands to 51.2
Base Case $210.44 (+102%)
Market implied 100.0%, PE stable at 46.6
Bear Case $71.55 (-32%)
Severe decline -20.0%, PE contracts to 39.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: August 03, 2026 2:54 AM ET
Data refreshes hourly during market hours. Next update: 3:54 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
NEUTRAL
Recent Transactions
Ro Khanna SELL 2026-02-24
Michael T. McCaul BUY 2026-02-20

Unlock Insider Activity

See real-time buying/selling by company executives for CVS.

Create Free Account

Already have an account? Log In

Top Rated Healthcare Plans Stocks

Top-rated stocks in Healthcare Plans by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
UNH
UnitedHealth Group Incor…
STRONG BUY
27 analysts
$475 50 HOLD
CI
Cigna Corp
STRONG BUY
25 analysts
$343 47 HOLD
ELV
Elevance Health Inc
STRONG BUY
22 analysts
$449 55 HOLD
HUM
Humana Inc
HOLD
26 analysts
$408 54 HOLD
CNC
Centene Corp
BUY
19 analysts
$71 43 HOLD

Advanced CVS Option Strategies

Professional options setups generated by AI based on today's CVS price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for CVS

CVS Technical Chart CVS Price Prediction CVS Earnings Date CVS Investment Advisor CVS Fair Price Analyzer CVS Options Advisor CVS Options Chain CVS Options Analysis CVS Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals